Clinical usefulness of <scp>MLC</scp>s in robotic radiosurgery systems for prostate <scp>SBRT</scp>

摘要

Abstract Stereotactic body radiation therapy ( SBRT ) using recently introduced multileaf collimators ( MLC ) is preferred over circular collimators in the treatment of localized prostate cancer. The objective of this study was to assess the clinical usefulness of MLC s in prostate SBRT by comparing the effectiveness of treatment plans using fixed collimators, variable collimators, and MLC s and by ensuring delivery quality assurance ( DQA ) for each. For each patient who underwent conventional radiation therapy for localized prostate cancer, mock SBRT plans were created using a fixed collimator, a variable collimator, and an MLC . The total MU s, treatment times, and dose – volume histograms of the planning target volumes and organs at risk for each treatment plan were compared. For DQA , a phantom with a radiochromic film or an ionization chamber was irradiated in each plan. We performed gamma‐index analysis to evaluate the consistency between the measured and calculated doses. The MLC ‐based plans had an ~27% lower average total MU than the plans involving other collimators. Moreover, the average estimated treatment time for the MLC plan was 31% and 20% shorter than that for the fixed and variable collimator plans respectively. The gamma‐index passing rate in the DQA using film measurements was slightly lower for the MLC than for the other collimators. The DQA results acquired using the ionization chamber showed that the discrepancies between the measured and calculated doses were within 3% in all cases. The results reinforce the usefulness of MLC s in robotic radiosurgery for prostrate SBRT treatment planning; most notably, the total MU and treatment time were both reduced compared to the cases using other types of collimators. Moreover, although the DQA results based on film dosimetry yielded a slightly lower gamma‐index passing rate for the MLC than for the other collimators, the MLC accuracy was determined to be sufficient for clinical use.